

1/17

BEST AVAILABLE COPY




Fig. 1A




Fig. 1B





Fig. 1C





Fig. 2A



3/17




Fig. 2B








Fig. 2C



TMS1

β-actin



5/17



Fig. 3C





Fig. 3D



6/17




Fig. 4A






Fig. 4B



Tumor/Normal Pairs

1N	1T	2N	2T	3N	3T	4N	4T	5N	5T	6N	6T
U	U	U	U	U	U	U	U	U	U	U	U
M	M	M	M	M	M	M	M	M	M	M	M



7N	7T	8N	8T	9N	9T	10N	10T	11N	11T	12N	12T
U	U	U	U	U	U	U	U	U	U	U	U
M	M	M	M	M	M	M	M	M	M	M	M





Fig. 4C



8/17





Fig. 5A



TMS1	AAKPGHFDQRAALIARVTN--VEMHDAAYG-KVITDEQYQAVRAE--PIINPSKMRKLFSTPAWNWTCKDILLQAIR--ESQSYLVEDLERS
CARD4	ESHPHIQLKSNRELLVTHIRN--TQCIVDNKNDYFSAEDABIVCAC--PIQPDVIRKIADLVQSKGEVSEFFELYLQQADAYVDLRPWLL
RICK	QPGIAQQWIOSKREDIVNQMTACLNQSGDA--SRDLIMKEDYELVSTK--PRTSKVRQ--MTTDTIQGEFAKIVVQK--DNKQMGLOPYPEI
procaspase-1	---MADKVIKEKRLFIRSMGEGTINGHDELLQTRVINKKEEMKVKREN-ALVMDKTRALIDSVIPKCAQCQICITTYTC--EEDSYLAGTGLS
procaspase-2	MHPHQETKKNRVIKAKQLL---SESEHEHMEKDL--FLFMRBLQAK--VGSFSQNVENLLPKRCPQAFDAFCEAR--ETKQGHLEDMLLT
procaspase-9	NDEADRRLEPRCRLRVEELQV---DQINQVGLSRELFPRPHMIEDIQRAGSGSRRDQARQ--HIDLETRGSQLPLRTSCIE--DTGQDMIASFLRT
CIAP-1	MASDDLSLRKRMALFQQLTC--VLPLEDNLFKANVINKQEHDIKQK--TQIPLQARELIDTILLVKGNANAEKNCIK--EIDSTLYKNIFVQ
RAIDD	MEARDKQVRSLSLLEFGAEVLV--EGLVLYQYQEGLEFENHIQETNAQ--TIGLR--TMTL--HIDILPSRCPKAFDTLDSIQ--EFPWVREKLKKAR
Bc110	LTEVKKDALENLRVYCEKIIA---ERHFDHURAKKLSREDTFETSCR--TSSRKTRAGKLGDIYIQ--ENPKGLDTLVESTPREKTQNFIIQKITD
Apaf-1	MDAKARNCLQHQHEAELEKDIKT---SYLMDHMTSDGF--HISEEEKVRNE--PIQQQRAAM--LKMILLKKNDSYVSEYNA--LHEGYKDLAALZHDG

Fig. 5B

TMS1 Compositions and Methods of Use
Paula M. Vertino
Docket No.: E0355.70003US00







Fig. 5D



12/17




Fig. 6A




Fig. 6B





Fig. 6C



13/17




Fig. 7A




Fig. 7B





Fig. 8A






Fig. 8B



16/17




Fig. 9A





Fig. 9B



myc TMS1

myc TMS1 Δ 100-195

<u>Construct</u>	<u>Aggregates</u>	<u>Cytoplasmic Staining</u>
mycTMS1	303 (55%)	249 (45%)
mycTMS1 Δ 100-195	7 (1%)	511 (99%)

Fig. 9C

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.